Why connected diagnostics companies stall at the hospital door
The technology works. It passed the bench tests, the pilot study, and the regulatory pre-submission. Then it hit a hospital procurement committee — and stopped.
This is the most common story in connected diagnostics. A compelling product, a clear clinical use case, strong IP, and a founding team that has answered every technical question. Yet the deployment timeline stretches from months into years. The product does not fail. The process does.
Understanding why requires a clear-eyed look at what hospital procurement actually is — and what it is not.
Procurement is not a technical decision
Hospital procurement committees do not evaluate products the way engineers do. They evaluate risk: clinical risk, IT integration risk, budget cycle risk, vendor risk, and regulatory liability. A diagnostics device, no matter how well-validated, arrives at a committee table as an unknown. The burden of proof is not just technical — it is institutional.
The committee's default answer is no. Not because the product is inadequate, but because yes requires work: budget allocation, IT review, QA sign-off, legal review of the supply contract, and clinical champion sign-off. Every yes creates internal accountability. No requires none of that.
Companies that treat procurement as a technical conversation — focusing on clinical data, feature comparisons, and price per test — are solving the wrong problem.
The five stall points
No internal champion with budget authority. A clinical department may love the product. If the head of department does not control the capital budget and is not allied with the CFO or procurement lead, that enthusiasm produces nothing. The champion must have both conviction and authority.
EU MDR documentation gaps. Hospital QA departments have become significantly more demanding since the EU Medical Device Regulation came into full effect. A device that sailed through FDA clearance may still face months of additional documentation requests in European hospital environments. Clinical Affairs teams at innovative companies often underestimate this.
IT governance. Connected diagnostics means data leaving the device. Every hospital IT department wants to know: where does the data go, who owns it, how is it encrypted in transit and at rest, and what happens to patient data if the vendor relationship ends. These questions are not unreasonable. But they require answers prepared in advance, not discovered during the procurement review.
No reference site. Hospital procurement committees are deeply risk-averse, and the single most effective risk reduction tool is a comparable deployment at a peer institution. Without a European reference case, every procurement conversation starts from zero. The first site is the hardest by a factor of ten. This is not metaphor — it is the observed reality of every connected diagnostics commercial cycle.
Wrong entry point. Cold outreach to procurement departments, responses to public tenders, or introductions via distributor networks are low-conversion paths for novel diagnostics products. The effective entry is through the clinical department head who feels the problem the device solves. That person must then be coached and supported to navigate their own internal procurement process. Most external sales teams do not have the relationships or the institutional knowledge to do this.
What actually moves a procurement committee
Three things shorten the cycle consistently.
First, a mapped stakeholder network before the first meeting. Who chairs procurement, who controls the IT review, who is the relevant clinical champion, and who has used your category before. Arriving at a hospital without this map means the first three months are reconnaissance, not selling.
Second, pre-answered objections. Every standard objection — data sovereignty, MDR documentation, integration complexity, budget timing — should have a prepared, written response ready before the first committee presentation. Committees move faster when they do not need to ask the same question twice.
Third, a structured pilot design. The first deployment at any institution should be designed as a reference case from day one: defined success metrics, documented outcomes, a named contact willing to speak to other procurement teams. A good pilot does not just prove the technology — it builds the commercial asset that accelerates every subsequent deal.
Most connected diagnostics companies are built by clinicians and engineers. That is appropriate — the product requires both disciplines. What is frequently absent is the commercial layer that understands regulated procurement: how hospitals buy, who the decision-makers actually are, how to navigate IT and QA reviews in parallel with clinical evaluation, and how to turn a pilot into a permanent deployment.
This is not a criticism. It is a structural gap that shows up at roughly the same point in every commercial cycle — after the clinical evidence is strong, after the regulatory pathway is clear, and before the first signed contract.
The companies that close that gap fastest are the ones that bring in commercial expertise with direct institutional relationships and a track record of managing the entire procurement journey — from first clinical conversation to live deployment.
The technology was never the problem. The door was.
Comments